Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-01-15
2010-02-16
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S362000
Reexamination Certificate
active
07662823
ABSTRACT:
This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
REFERENCES:
patent: 5023265 (1991-06-01), Scherlock et al.
patent: 5124327 (1992-06-01), Greenlee et al.
patent: 5424329 (1995-06-01), Boschelli et al.
patent: 6140349 (2000-10-01), Caldwell et al.
patent: 6150530 (2000-11-01), Kempf et al.
patent: 6476034 (2002-11-01), Wang et al.
patent: 6825201 (2004-11-01), Wang et al.
patent: 7354924 (2008-04-01), Wang et al.
patent: 7501420 (2009-03-01), Wang et al.
patent: 2002/0061892 (2002-05-01), Wang et al.
patent: 2004/0063744 (2004-04-01), Wang et al.
patent: 2005/0209246 (2005-09-01), Ueda et al.
patent: 2006/0167044 (2006-07-01), Arnaiz et al.
patent: 2007/0155702 (2007-07-01), Chen et al.
patent: 2007/0249579 (2007-10-01), Wang et al.
patent: 0530907 (1993-03-01), None
patent: WO 93/01181 (1993-01-01), None
patent: WO 95/04742 (1995-02-01), None
patent: WO 96/11929 (1996-04-01), None
patent: WO 00/07652 (2000-02-01), None
patent: WO 00/71535 (2000-11-01), None
patent: WO 0076521 (2000-12-01), None
patent: WO 01/62255 (2001-08-01), None
patent: WO 02/04440 (2002-01-01), None
M. Font, et al., “Indoles and Pyridazino[4,5[b]indoles as Nonnucleoside Analog Inhibitors of HIV-1 Reverse Transcriptase,” Eur. J. Med. Chem., 30, pp. 963-971, 1995.
D. L. Romero, et al., J. Med. Chem., 36, pp. 1505-1508, 1993.
S.D. Young, et al., “2-Heterocyclic Indole-3-Sulfones as Inhibitors of HIV-1 Reverse Transcriptase,” Bioorganic & Medicinal Chemistry Letters, 5(5), pp. 491-496, 1995.
M.J. Genin, et al., “Synthesis and Bioactivity of Novel Bis(Heteroaryl) Piperazine (BHAP) Reverse Transcriptase Inhibitors: Structure-Activity Relationships and Increased Metabolic Stability of Novel Substituted Pyridine Analogs,” J. Med. Chem., 39, pp. 5267-5275, 1996.
R. Silvestri, et al., Antiviral Chemistry & Chemotherapy, 9, pp. 139-148, 1998.
A. Fredenhagen, et al., “Semicochiliodinol A and B: Inhibitors of HIV-1 Protease and EGF-R Protein Tyrosine Kinase Related to Asterriquinones Produced by the FungusChrysosporium merdarium,” Journal of Antibiotics, 50(5), pp. 395-401, 1997.
M. Kato, et al., “New 5HT3(Serotonin-3) Receptor Antagonists. IV. Synthesis and Structure-Activity Redlationships of Azabicycloalkaneacetamide Derivatives.” Chem. Pharm. Bull., 43(8), pp. 1351-1357, 1995.
V. Levacher, et al., “Broadening in the Scope of NADH Models by Using Chiral and Non-chiral Pyrrolo[2,3[b]Pyridine Derivatives,” Tetrahedron, 47(3), pp. 429-440, 1991.
Wang, Tao et al., “Discovery of 4-Benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridine-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): A Novel HIV-1 Attachment Inhibitor That Interferes with CD4-gp120 Interactions,” Journal of Medicinal Chemistry, 2003, vol. 46, No. 20, pp. 4236-4239.
Kadow John F.
Matiskella John D.
Meanwell Nicholas A.
Regueiro-Ren Alicia
Ueda Yasutsugu
Bernhardt Emily
Bristol--Myers Squibb Company
Levis John F.
LandOfFree
Pharmaceutical formulations of substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulations of substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations of substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4168512